17,261 trials
Heartburn
Primary: Measure: Number of Participants With no Heartburn (Post Treatment) Following Consumption of Heartburn-inducing Meal — 0; 2; 1; 0 participants
Anemia
Primary: Maximum Observed Serum Concentration (Cmax) — 8545.33 ug/dL
Head and Neck Cancer
Primary: 2-year Progression-free Survival Rate — 47 proportion of participants
Postoperative Nausea and Vomiting
Primary: Experienced Post-operative Nausea or Vomiting — 25; 29; 20; 30 participants
Postmenopausal Osteoporosis
Primary: Percentage Change From Baseline Serum Type-1 Collagen C-telopeptide (CTX) 75 mg & 100 mg DRFB Tablet Compared With 150 mg IRBB Tablet, Month 4, ITT Population — -41.235…
Glaucoma
Primary: Mean Change in the Peak Intraocular Pressure (IOP) Measured Two Hours After Study Drug Administration at Week 12 Compared to Baseline IOP. — -3.73 mmHg — p=<0.0001
Acute Myelogenous Leukemia · Acute Myeloid Leukemia
Primary: Percentage of Participants Achieving Overall Remission (OR) After No More Than Two Cycles (Approximately Month 2) — 45.5; 37.5; 8.0; 3.6 percentage of participants
Lung Cancer
Primary: Patient Response — 2; 1; 2; 27 participants
Multiple Sclerosis
Primary: Number of Patients Free of Gadolinium-enhanced T1-Weighted Magnetic Resonance Imaging (MRI) Lesions at Both Month 3 and Month 6 — 43; 35; 21 Participants
Amblyopia
Primary: Distribution of Amblyopic Eye Visual Acuity Letter Scores at 9 Weeks After Starting Levodopa — 2; 5; 2; 0 participants
Gram-Positive Bacterial Infections
Primary: Clinical Response (Cure, Failure, or Indeterminate) as Determined by the Investigator Based the Presence or Absence of Clinical Signs and Symptoms Associated With…
Amyotrophic Lateral Sclerosis · Lou Gehrig's Disease
Primary: Change in the ALS Functional Rating Scale-revised (ALSFRSr) Score. — 8.80; 9.44; 10.9 units on a scale — p=0.14
Influenza
Primary: Number of Seroconverted Subjects After the Second Dose of Pandemrix and After Vaccination With Fluarix — 79; 82; 40; 22 subjects
Breast Cancer · Metastasis
Primary: Number of Participants With Complete Response (CR) or Partial Response (PR) — 2; 0 participants
Neoplasms, Uterine Cervix · Metastatic Cervical Cancer
Primary: Progression-free Survival (PFS) in Interim Analysis — 12.6; 12.6; 17.9 Weeks — p=0.535